Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Caspian Oliai

Title(s)HS Assistant Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Overview 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study. Blood. 2026 May 19. Muffly L, Frey NV, Roloff GW, Park JH, Dholaria B, Advani AS, Bachanova V, Cassaday RD, Daunov M, Dykes KC, Irizarry Gatell V, Grunwald MR, Hilal T, Hill LC, Jamy O, Kota VK, Kumaran M, Lin C, Logan AC, Luskin MR, O'Dwyer KM, Oliai C, Oluwole OO, Sasine JP, Schwartz MS, Solh MM, Stock W, Tsai SB, Ulrickson ML, Vasu S, Wang ES, Yalniz FF, Strickland SA, Leonard JT, Shah BD, Aldoss I. PMID: 42154904.
      View in: PubMed   Mentions:    Fields:    
    2. Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 Apr 23; 147(17):2011-2017. Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, Boccucci J, Ulrickson M, Pradeep R, Hill L, Tsai SB, O'Connor T, Sandhu K, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Bobillo SO, Hilal T, Park JH, Valtis YK, Faramand R, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine J, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran MV, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock W, Schwartz M, Byrd K, Yalniz F, Bachanova V, Tracy S, Yaghmour G, Irizarry Gatell VM, Jackson CW, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai CH, Muffly LS. PMID: 41643192.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia. Leukemia. 2026 May; 40(5):880-893. Li YR, Shen X, Chen Y, Zhu Y, Huang J, Oliai C, Yang L. PMID: 41888396; PMCID: PMC13149322.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    4. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12; 147(11):1168-1177. Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C. PMID: 41385341; PMCID: PMC13123417.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351). Leuk Lymphoma. 2026 Feb; 67(3):718-721. Ngo D, Kaleka G, Yang D, Mokhtari S, Tinajero J, Marcucci G, Nakamura R, Pullarkat V, Oliai C, Salhotra A. PMID: 41194510.
      View in: PubMed   Mentions:    Fields:    
    6. Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Oct; 23(10). Loren AW, Mielcarek M, Bolaños-Meade J, Brammer J, Cowden M, Di Stasi A, El-Jawahri A, Elmariah H, Gundabolu K, Gutman J, Ho V, Hoeg RT, Horwitz M, Jamy O, Kassim A, Kharfan-Dabaja M, Lee L, Logan A, Luszcak C, Magenau JM, Martin TG, Mittal V, Moreira J, Muffly L, Nakamura R, Nawas M, Nieto Y, Ninos C, Oliai C, Papanicolaou G, Pidala J, Randolph B, Schroeder MA, Tessier J, Topal J, Tzachanis D, Varshavsky-Yanovsky AN, Jones F, Stehman K. PMID: 41067275.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    7. Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025 Aug 26; 9(16):4081-4089. Muhsen IN, Roloff GW, Faramand R, Othman T, Valtis Y, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail N, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai CH, Shaughnessy P, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz M, Sasine JP, Kumaran M, Frey N, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. PMID: 40334068; PMCID: PMC12359224.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Bone Marrow Transplant. 2025 Nov; 60(11):1465-1471. O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B. PMID: 40849364; PMCID: PMC12583187.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO Open. 2025 May; 10(5):105081. Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime-Casas S, Barragan-Carrillo R, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M. PMID: 40315659; PMCID: PMC12098135.
      View in: PubMed   Mentions: 1  Translation:Humans
    10. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat Commun. 2025 Feb 01; 16(1):1248. Li YR, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z, Zhu E, Tian Y, Huang J, Rezek V, Kitchen S, Hsiai T, Zhou JJ, Wang P, Chai-Ho W, Park S, Seet CS, Oliai C, Yang L. PMID: 39893165; PMCID: PMC11787387.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimals
    11. CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leuk Lymphoma. 2025 Apr; 66(4):773-779. Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. PMID: 39689718.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    12. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147. Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. PMID: 39093952; PMCID: PMC11707416.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    13. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 Feb 10; 43(5):558-566. Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L, ROCCA Consortium. PMID: 39418622; PMCID: PMC12070553.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    14. Delayed immune tolerance through donor haematopoietic stem cell infusion 14 months after kidney transplantation. Lancet. 2024 10 05; 404(10460):1346. Lum EL, Nassiri N, Kogut N, Oliai C, Raldow A, Reed EF, Veale JL. PMID: 39368842.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Effectiveness of Single-Fraction, Low-Dose, Bilateral Whole Lung Radiation Therapy for Diffuse Alveolar Hemorrhage Secondary to Extramedullary Hematopoiesis: A Case Report and Review of the Literature. Adv Radiat Oncol. 2024 Jul; 9(7):101506. Neilsen BK, Sleightholm RL, Gower A, Tsai SC, Schiller GJ, Oliai C, Lee A, Raldow A, Tenn S, Venkat PS. PMID: 38799111; PMCID: PMC11127181.
      View in: PubMed   Mentions:
    16. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 01; 65(1):69-77. Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G. PMID: 37801340.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538. Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. PMID: 37026796; PMCID: PMC10425681.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    18. Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation. Microorganisms. 2023 Aug 16; 11(8). Yang S, Multani A, Garrigues JM, Oh MS, Hemarajata P, Burleson T, Green NM, Oliai C, Gaynor PT, Beaird OE, Winston DJ, Seet CS, Schaenman JM. PMID: 37630656; PMCID: PMC10460003.
      View in: PubMed   Mentions: 10  
    19. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023 07; 29(7):449.e1-449.e7. Ahmed N, Wesson W, Mushtaq MU, Porter DL, Nasta SD, Brower J, Bachanova V, Hu M, Nastoupil LJ, Oluwole OO, Patel VG, Oliai C, Riedell PA, Bishop MR, Shah GL, Perales MA, Schachter L, Maziarz RT, McGuirk JP. PMID: 37120134; PMCID: PMC11027185.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    20. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Cancer Discov. 2023 03 01; 13(3):580-597. Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY. PMID: 36416874; PMCID: PMC9992104.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    21. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Netw. 2023 02; 21(2):108-115. Saad A, Loren A, Bolaños-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Kharfan Dabaja M, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA. PMID: 36791762.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    22. Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series. Leuk Lymphoma. 2023 02; 64(2):507-510. Gaut D, Oliai C, Mead M. PMID: 36647839.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis. Clin Lymphoma Myeloma Leuk. 2022 10; 22(10):e947-e957. Othman T, Penaloza J, Zhang S, Daniel CE, Gaut D, Oliai C, Brem EA, Baweja A, Ly J, Reid J, Pinter-Brown L, Lee M, Abdulhaq H, Tuscano J. PMID: 35858904.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    24. Diminished durability of chimeric antigen receptor T-cell efficacy with severe or prolonged postinfusion cytopenias. Am J Hematol. 2022 07; 97(7):E249-E255. Tabbara N, Sharp J, Gaut D, Pham TTD, Tang K, Oliai C, Sim MS, Schiller G, Young P, Sasine JP. PMID: 35358346.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    25. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. Am J Hematol. 2022 06 01; 97(6):E191-E194. Kennedy VE, Hui G, Azenkot T, Gaut D, Wieduwilt MJ, Oliai C, Jonas BA, Mittal V, Logan AC, Muffly LS, Mannis GN. PMID: 35266185.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    26. Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL. Leuk Res Rep. 2021; 16:100260. Tabbara N, Gaut D, Oliai C, Lewis T, de Vos S. PMID: 34354920; PMCID: PMC8322434.
      View in: PubMed   Mentions: 8  
    27. How to address second and therapy-related acute myelogenous leukaemia. Br J Haematol. 2020 01; 188(1):116-128. Oliai C, Schiller G. PMID: 31863469.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    28. Clinical features of pseudocirrhosis in metastatic breast cancer. Breast Cancer Res Treat. 2019 Sep; 177(2):409-417. Oliai C, Douek ML, Rhoane C, Bhutada A, Ge PS, Runyon BA, Wang X, Hurvitz SA. PMID: 31175499; PMCID: PMC6664810.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    29. Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review. Anticancer Res. 2018 Dec; 38(12):6927-6930. Howell G, Oliai C, Schiller G. PMID: 30504411.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia. Curr Treat Options Oncol. 2018 10 25; 19(12):63. Levin-Epstein R, Oliai C, Schiller G. PMID: 30362051.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    31. Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer. J Radiat Oncol. 2016; 5:187-195. Oliai C, Bernetich M, Brady L, Yang J, Hanlon A, Lamond J, Arrigo S, Good M, Mooreville M, Garber B, Lanciano R. PMID: 27335630; PMCID: PMC4893387.
      View in: PubMed   Mentions: 7  
    32. Breast cancer: The debate over post-mastectomy radiotherapy should continue. Nat Rev Clin Oncol. 2015 Oct; 12(10):567-8. Oliai C, Hurvitz SA. PMID: 26323387.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    33. SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines. Front Oncol. 2014; 4:312. Bernetich M, Oliai C, Lanciano R, Hanlon A, Lamond J, Arrigo S, Yang J, Good M, Feng J, Brown R, Garber B, Mooreville M, Brady LW. PMID: 25426447; PMCID: PMC4227393.
      View in: PubMed   Mentions: 17  
    34. Radioprotectants to reduce the risk of radiation-induced carcinogenesis. Int J Radiat Biol. 2014 Mar; 90(3):203-13. Oliai C, Yang LX. PMID: 24164532.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    35. Clinical experience using accelerated partial breast irradiation for ductal carcinoma in situ. Breast J. 2013 Mar-Apr; 19(2):217-9. Fisher B, Oliai C, Wong M, Soni P, Shaikh T, Komarnicky LT. PMID: 23458220.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol. 2013 Mar; 2(1):63-70. Oliai C, Lanciano R, Sprandio B, Yang J, Lamond J, Arrigo S, Good M, Mooreville M, Garber B, Brady LW. PMID: 23504305; PMCID: PMC3594824.
      View in: PubMed   Mentions: 27  
    37. Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):733-40. Oliai C, Fisher B, Jani A, Wong M, Poli J, Brady LW, Komarnicky LT. PMID: 22440041.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansPHPublic Health
    38. Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo. J Immunol. 2011 Apr 15; 186(8):4599-608. Dolfi DV, Duttagupta PA, Boesteanu AC, Mueller YM, Oliai CH, Borowski AB, Katsikis PD. PMID: 21389258.
      View in: PubMed   Mentions: 44     Fields:    Translation:AnimalsCells
    Caspian's Networks
    Concepts (141)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (49)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-22-g09c84f92 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California